Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device. Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver Inovio’s INO-4800 COVID-19 vaccine candidate directly into the skin. […]
MIT researchers think they’ve found a way to get more particles through a syringe
Researchers at the Massachusetts Institute of Technology (MIT) are touting a computational model that could prevent microparticle clogging during injections. Microparticles, which are about the size of a grain of sand, can be difficult to inject if they get clogged in a typical syringe. The research team at MIT developed this new model that determines […]
AbbVie gains U.S. nod for $63B Allergan takeover
Pharmaceutical giant AbbVie (NYSE:ABBV) has won U.S. antitrust approval for its purchase of Allergan (NYSE:AGN) for $63 billion in cash and stock. The purchase is seen as a hedge against the impending expiration of U.S. patents on AbbVie’s blockbuster drug, Humira. North Chicago-based AbbVie announced the deal in June 2019, but ran up against U.S. Federal Trade Commission […]
OncoSec, Inovio testing COVID-19 vaccines
OncoSec Medical (NSDQ:ONCS) and Inovio Pharmaceuticals (NSDQ:INO) announced that they are testing potential COVID-19 vaccines after the latter received investigational new drug clearance from the FDA. Inovio received an IND nod, while OncoSec’s is pending, but both companies are pursuing a first-in-human Phase 1 clinical trial for their vaccines, according to separate news releases. OncoSec is using […]
TriSalus touts data for pressure-enabled drug-delivery tech
TriSalus Life Sciences touted results today from a Phase Ib trial of its pressure-enabled drug-delivery tech for immunotherapy. The company reported that delivering a concentrated dose of CAR-T cells at the site of a solid tumor using its technology was safe and contributed to positive clinical results. In the early-stage trial, five patients with carcinoembryonic […]
OncoSec shares fall on preliminary data from skin cancer trial
Shares in OncoSec Medical (NSDQ:ONCS) fell nearly -60% this morning after the company revealed preliminary data from its Phase IIb trial of intratumoral delivery of Tavo in people with unresectable, advanced melanoma. OncoSec’s lead product, Tavo, uses electroporation to deliver IL-12 directly into a patient’s tumor, triggering an immune response. As of Sept. 1, 21 people […]
Researchers develop nanodevice to deliver immunotherapy
Researchers at Houston Methodist Research Institute have created a nanodevice that can be used to deliver immunotherapy to treat triple-negative breast cancer. The tiny device is designed to be inserted directly into a tumor, delivering a localized, sustained-release dose of therapy and eliminating the need for patients to undergo IV treatments. The scientists described their […]
Ichor touts use of electroporation drug-delivery system in cervical cancer trial
Ichor Medical Systems said today that its TriGrid electroporation drug-delivery system was tapped for a Phase Ib/II clinical trial to administer an investigational therapeutic HPV DNA vaccine, GX-188E, developed by Genexine Inc. The trial is designed to test the efficacy of a DNA vaccine combined with an anti-PD-1 therapy in patients with HPV-induced advanced non-resectable […]
BioEclipse looks to synergistic therapies to topple stubborn cancers
For the last 20 years, Pamela Contag has studied cancer. And in that time, the world’s understanding of cancer has changed dramatically. “I remember when people were saying ‘One gene, one protein,” which we now know is wrong,” she told Drug Delivery Business News. “And then we thought cancer was a disruption in proliferation and really […]
TapImmune adds cell therapy to peptide vaccine portfolio with Marker Therapeutics merger
TapImmune (NSDQ:TPIV) expanded its immuno-oncology capabilities today with a deal to acquire Marker Therapeutics and its clinical-stage, multi-antigen T cell therapy platform. Details regarding merger-related financing were not disclosed, but TapImmune said it is in talks with a syndicate of institutional investors to fund the company until 2020. “I believe that the new therapies we are […]
- 1
- 2
- 3
- …
- 6
- Next Page »
